Moreover, subgroup analysis illustrated that co-expression of BRD4 and PD-L1 predicts poor OS in non-APL patients, patients under 60 years old, and those with intermediate/high risk. This evidence concerns the gene BRD4 and acute promyelocytic leukemia.